Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Phase III failure of the high-profile Alzheimer's disease drug dimebon is a setback not only for Alzheimer's drug development, but also for Pfizer, which very much needs pipeline successes to offset upcoming patent losses, and for Medivation, whose near-term future hinges on the drug
You may also be interested in...
Will Cabazitaxel Success Derail Other Prostate Cancer Trials?
The release of positive Phase III results for Sanofi-Aventis' next-generation chemotherapy agent cabazitaxel in hormone-resistant prostate cancer could put a damper on recruitment for clinical trials of other late-stage drug trials in the same indication
J&J And Elan Strike A Deal On Key Alzheimer's Disease Assets
Six months after announcing it was looking at strategic alternatives, Elan's beleaguered management has found a way to address its challenges: It announced July 2 that it is selling its Alzheimer's immunotherapy program (AIP), which includes the high-profile Alzheimer's disease drug bapineuzumab and all related assets, to Johnson & Johnson for what essentially amounts to $500 million in the near-term and a commitment from J&J to buy an 18.4 percent stake in Elan for $1 billion
Pfizer Finds Backup For Aricept In Medivation’s Dimebon
Medivation Alzheimer’s candidate is unique for its disease-modifying potential.